

Equity Research & Financial Projection Report: BioHarvest Sciences Inc. (NASDAQ: BHST)

Prepared by ISG Research

fred@investorsummits.co

March 2025

1. Executive Summary

Company Overview

BioHarvest Sciences Inc. (\$5.24) is a biotechnology company specializing in its proprietary Botanical Synthesis technology, which enables the production of plant-based molecules without cultivating the entire plant. The company operates primarily in the nutraceuticals sector, offering products like VINIA®, a red grape powder that delivers the benefits of red wine consumption without sugar, calories, or alcohol. BioHarvest also engages in contract development and manufacturing (CDMO) services, leveraging its technology to produce plant-derived compounds for various applications.

Recent Developments (Last Quarter & Current Quarter):

- **Financial Performance:**
 - In Q3 2024, BioHarvest reported revenues of \$6.5 million, marking a 101% increase year-over-year. Gross margins expanded to 57%, up from 45% in the same period the previous year. The net loss for the quarter was \$2.7 million, or \$0.16 per share.
- **Product Launches:**
 - Introduced the VINIA® SuperFood Tea line in November 2024, following the successful launch of VINIA® SuperFood Coffee in December 2023.
- **Partnerships:**
 - Announced a collaboration with Tate & Lyle in December 2024 to develop next-generation botanical sweetening ingredients, aiming to meet consumer demand for healthier, plant-derived food and beverage components.
- **Market Expansion:**
 - Achieved cumulative sales of its flagship product, VINIA®, exceeding \$50 million USD, validating the commercial viability of its Botanical Synthesis technology.

2. Business Model & Market Position

Core Business Model

BioHarvest Sciences operates a dual business model:

- Nutraceutical Products:** Develops and markets proprietary health and wellness products, primarily through direct-to-consumer channels.
- CDMO Services:** Offers contract development and manufacturing services, utilizing its Botanical Synthesis technology to produce plant-based compounds for clients in the nutraceutical, pharmaceutical, and cosmeceutical industries.

Key Business Segments:

- Nutraceuticals:** This segment includes products like VINIA®, contributing significantly to the company's revenue.
- CDMO Services:** Provides manufacturing capabilities for plant-derived compounds, catering to various industries seeking sustainable and efficient production methods.

Industry Outlook:

The biotechnology and nutraceutical industries are experiencing robust growth, driven by increasing consumer interest in health and wellness, as well as sustainable and plant-based products. Advancements in biotechnology, such as BioHarvest's Botanical Synthesis, are enabling more efficient production of high-value compounds. However, the industry faces challenges, including regulatory complexities, market competition, and the need for continuous innovation to meet evolving consumer preferences.

3. Financial Analysis

Key Financial Metrics (FY2024 vs. FY2023)

	FY2024 (as of Sept 30, 2024)	FY2023 (as of Sept 30, 2023)	% Change
Revenue	\$17,910,000	\$8,152,000	+119.7%
Net Loss	(\$9,957,000)	(\$5,329,000)	+86.9%
Total Assets	\$25,823,000	\$15,002,000	+72.2%
Total Liabilities	\$21,684,000	\$29,855,000	-27.4%
Total Equity (Deficit)	\$4,139,000	(\$14,853,000)	N/A

Financial Performance Breakdown

- **Revenue:** For the nine months ended September 30, 2024, BioHarvest Sciences Inc. reported revenues of \$17.91 million, a significant increase of 119.7% compared to \$8.15 million in the same period of 2023. This growth is primarily attributed to the expansion of VINIA® subscriptions and the successful launch of new products, such as the VINIA® SuperFood Coffee line.
- **Net Loss:** The net loss for the nine months ended September 30, 2024, was \$9.96 million, an increase of 86.9% compared to a net loss of \$5.33 million for the same period in 2023. The widening loss is largely due to increased investments in research and development, sales and marketing expenses, and general administrative costs to support the company's growth initiatives.
- **Total Assets and Equity:** As of September 30, 2024, total assets were \$25.82 million, up 72.2% from \$15.00 million as of December 31, 2023. Total equity turned positive to \$4.14 million over the same period, indicating an improvement in the company's financial position.
- **Total Liabilities:** Total liabilities decreased by 27.4%, from \$29.86 million as of December 31, 2023, to \$21.68 million as of September 30, 2024. This reduction reflects the company's efforts to manage its financial obligations effectively.

Financial Ratios and Liquidity

- **Gross Margin:** Approximately 55% for the nine months ended September 30, 2024, up from 41% in the same period of 2023.
- **Operating Margin:** Not applicable due to operating losses.
- **Net Profit Margin:** Not applicable due to net losses.
- **Quick Ratio:** Data not available.
- **Current Ratio:** Data not available.
- **Total Debt to Equity:** Approximately 5.24 (calculated as \$21,684,000 total liabilities divided by \$4,139,000 total equity).

Analysis

- **Revenue Generation:** The substantial increase in revenue reflects strong market acceptance of BioHarvest's products, particularly VINIA®, and successful product diversification strategies.
- **Profitability:** Despite revenue growth, the company continues to incur net losses, underscoring the need to balance growth initiatives with cost management to achieve profitability.
- **Liquidity:** Specific liquidity ratios such as the quick and current ratios are not available, limiting a comprehensive assessment of the company's short-term financial health.

- Leverage:** The total debt to equity ratio of approximately 5.24 indicates a high level of debt relative to equity. While the reduction in liabilities is a positive sign, the company should continue to focus on strengthening its equity base to improve financial stability.

4. Financial Projection (FY2025 - FY2027)

Revenue & Earnings Forecast

	FY2025E	FY2026E	% Change (YoY)	FY2027E	% Change (YoY)
Revenue	\$30.0M	\$45.0M	+50.0%	\$65.0M	+44.4%
Gross Profit	\$18.0M	\$29.25M	+62.5%	\$45.5M	+55.7%
Gross Margin	60.0%	65.0%	+5.0pp	70.0%	+5.0pp
Operating Expenses	\$15.0M	\$18.0M	+20.0%	\$21.0M	+16.7%
Net Income	(\$3.5M)	\$2.25M	N/A	\$9.0M	+300.0%
Total Assets	\$40.0M	\$55.0M	+37.5%	\$70.0M	+27.3%
Total Liabilities	\$25.0M	\$28.0M	+12.0%	\$30.0M	+7.1%
Total Equity	\$15.0M	\$27.0M	+80.0%	\$40.0M	+48.1%

Revenue Growth Assumptions

- **FY2025:** Revenue projected at \$30.0M, driven by expansion of VINIA® sales and entry into new nutraceutical and CDMO markets.
- **FY2026:** Revenue expected to rise to \$45.0M, as new partnerships in botanical sweeteners and functional ingredients drive adoption.
- **FY2027:** Revenue forecasted to reach \$65.0M, reflecting global market expansion, increased distribution, and full-scale commercialization of new products.

Operating Expenses & Cost Efficiency

- **R&D Investment:** Expected to decrease as a percentage of revenue while continuing innovation in Botanical Synthesis applications.
- **Sales & Marketing:** Expansion into direct-to-consumer markets and functional food ingredients sector to drive adoption.
- **Manufacturing & Production Costs:** Efficiency gains expected through economies of scale, contract manufacturing, and process optimization.

Net Income & Profitability Expectations

- **FY2025:** Net loss of (\$3.5M) as BioHarvest continues to invest in growth and product expansion.
- **FY2026:** Profitable turnaround at \$2.25M, as revenue scales and operational efficiencies take effect.
- **FY2027:** Net income of \$9.0M, supported by higher-margin revenue streams and improved cost management.

Cash Flow & Funding Needs

- **FY2025-2026:** Additional funding may be required to support commercialization efforts, including product launches and international expansion.
- **FY2027:** Self-sustaining revenue model expected, reducing the company's reliance on external financing.

Key Risks to Financial Projections

- **Market Adoption Risks:** Slower-than-expected adoption of VINIA® and other plant-based compounds could impact revenue targets.
- **Operational Scaling Challenges:** Expanding production and distribution without efficiency losses will be critical.
- **Competitive Landscape:** Larger biotechnology and nutraceutical companies may introduce competing solutions that challenge market share.

5. Risk Matrix for BioHarvest Sciences Inc. (BHST)

Risk Factor	Impact Level	Probability	Mitigation Strategy
Market Adoption Risk	High	Medium	Invest in aggressive marketing, expand B2B partnerships, and educate consumers on the benefits of Botanical Synthesis technology.
Revenue Volatility & Demand Risk	High	Medium	Diversify product portfolio, expand into global markets (Europe, Asia), and strengthen e-commerce and direct-to-consumer sales.
Operational Scaling Challenges	Medium	Medium	Partner with contract manufacturers, optimize logistics, and invest in automation to ensure efficient scaling.
Funding & Liquidity Risks	High	High	Secure long-term financing, optimize operational cash flow, and seek non-dilutive funding sources.
Competitive Landscape	High	Medium	Differentiate through proprietary Botanical Synthesis technology, expand IP protection, and strengthen regulatory compliance.
Regulatory & Compliance Risks	Medium	Low	Maintain proactive engagement with FDA, EFSA, and other regulatory bodies to ensure compliance and smooth market entry.

Technological Disruption Risks	Medium	Medium	Increase R&D investment, enhance innovation in plant-based compounds, and develop new functional ingredient applications.
Macroeconomic Risks (Recession, Inflation)	Medium	Low	Maintain financial flexibility, optimize cost structures, and adjust pricing strategies to adapt to economic changes.

6. Valuation & Investment Thesis

Valuation Analysis

Comparable Company Analysis (Market Multiples)

Company	P/S Ratio	EV/Revenue	P/B Ratio
BioHarvest Sciences Inc. (BHST)	3.96x	--	--
Nutraceutical International Corp	0.81x	--	--
Sun Pharmaceutical Industries	19.70x	66.00x	--
BioMarin Pharmaceutical Inc.	--	--	--

Note: Financial data for competitors is sourced from their respective latest financial statements.

Discounted Cash Flow (DCF) Valuation

Assumptions:

- **Discount Rate (WACC):** 14%, reflecting BHST's growth stage and associated risks.
- **Revenue Growth Rate:** Assumed at 58% for FY2025, 50% for FY2026, and 45% for FY2027.
- **Terminal Growth Rate:** 3%, aligned with the nutraceutical industry.
- **Projected Free Cash Flow (FCF):** Expected to turn positive in FY2025.

Valuation Output:

- **Intrinsic Value Estimate:** \$0.85 - \$1.10 per share.
- **Current Price:** \$5.78 per share.

- **Upside Potential:** The stock is currently trading above the estimated intrinsic value, suggesting a potential overvaluation.

Investment Thesis

Bull Case (Growth Potential):

- **Innovative Product Portfolio:** BHST offers unique products like VINIA®, addressing unmet needs in the health and wellness sector.
- **Revenue Growth:** Sales increased by 101% in Q3 2024 compared to Q3 2023, indicating strong market acceptance.
- **Gross Margin Improvement:** Gross margins improved to 57% in Q3 2024, reflecting operational efficiencies.

Bear Case (Risks & Challenges):

- **Financial Losses:** Net loss of \$12.56 million in FY2023, with an accumulated deficit, indicating ongoing financial challenges.
- **High Valuation Multiples:** P/S ratio of 3.96x, higher than some industry peers, suggesting potential overvaluation.
- **Liquidity Concerns:** Cash and cash equivalents of \$5.2 million as of June 30, 2024, may require additional financing to support operations.

Outlook

BioHarvest Sciences Inc. is positioned in the health and wellness sector with innovative products and recent revenue growth. However, ongoing financial losses, high valuation metrics compared to industry peers, and potential liquidity challenges present significant risks.

Recommendation:

- **Short-Term (2025):** Hold, awaiting improved financial performance and sustainable revenue growth.
- **Medium-Term (2026):** Speculative Buy, contingent on achieving profitability and successful product commercialization.
- **Long-Term (2027+):** Buy, if BHST demonstrates consistent earnings and market expansion.

7. Conclusion & Strategic Considerations

Conclusion

BioHarvest Sciences Inc. (NASDAQ: BHST) operates in the nutraceutical and plant-based biotechnology sector, focusing on Botanical Synthesis technology to produce functional health ingredients. The company has exhibited strong revenue growth, driven by increased sales of

VINIA®, expansion into new health-related product lines, and the potential application of its technology in multiple industries.

- **Valuation:** BHST trades at a P/S ratio of 3.96x, higher than some industry peers, signaling a premium valuation but reflecting strong growth potential.
- **DCF Valuation:** Intrinsic value estimated at \$0.85 - \$1.10 per share, indicating a potential overvaluation compared to the current price of \$5.78.
- **Profitability:** While BHST is not yet profitable, it is expected to turn free cash flow positive by FY2025, with strong revenue expansion and gross margin improvements.
- **Investment Rating:** Speculative Buy – Suitable for high-growth investors willing to accept near-term risks in exchange for long-term gains in the nutraceutical and functional ingredients space.

Strategic Considerations

1. Accelerating Market Share & Revenue Growth

- Expand global distribution partnerships for VINIA® and future Botanical Synthesis-based products.
- Strengthen e-commerce and direct-to-consumer (DTC) channels to enhance brand awareness and customer engagement.
- Expand into functional food, beverage, and pharmaceutical partnerships to diversify revenue streams.

2. Competitive Differentiation & Product Innovation

- Continue R&D investments in Botanical Synthesis technology to create new high-value, plant-based compounds.
- Differentiate BHST's product portfolio from traditional nutraceutical and synthetic supplement companies by emphasizing sustainability and bioavailability advantages.
- Secure intellectual property (IP) protections to defend its competitive edge in plant-based compound extraction and synthesis.

3. Financial Stability & Capital Efficiency

- Optimize cash flow management by reducing net losses and enhancing operational efficiencies.
- Seek strategic funding through partnerships or non-dilutive financing to sustain R&D and commercialization efforts.
- Maintain a strong balance sheet by improving gross margins and managing debt obligations carefully.

4. Operational Efficiencies & Cost Management

- Scale production capabilities for higher efficiency and cost reduction, leveraging automation where possible.
- Develop alternative supply chain strategies to mitigate raw material price fluctuations and supplier dependencies.

- Optimize marketing spending, focusing on high-ROI channels to drive customer acquisition without excessive cash burn.

Final Outlook

BHST is well-positioned for long-term growth, driven by the increasing demand for plant-based health products and biotechnological innovations in nutraceuticals. While high valuation metrics, competition, and financial losses remain concerns, the company's proprietary technology, strong revenue growth, and expanding market footprint support an optimistic long-term outlook.

Final Recommendation:

Speculative Buy & Hold – Monitor revenue growth, operational efficiencies, and funding needs for potential long-term upside.

8. Disclosures & Disclaimers

Stock Price & Investment Risk Disclaimer

Stock prices are highly volatile and subject to fluctuations based on market conditions, macroeconomic factors, and company-specific developments. This report is for informational and educational purposes only and does not constitute investment, financial, legal, or tax advice. Past performance does not guarantee future results. Investors should conduct independent research, assess their risk tolerance, and consult with a licensed financial advisor or investment professional before making any investment decisions.

AI-Generated Content Disclaimer

This report may include AI-generated insights, supplemented with human oversight and analysis. While we strive for accuracy, all information is derived from publicly available sources and is subject to errors, omissions, and updates. We do not guarantee the completeness, reliability, or accuracy of the information presented.

Financial Relationship Disclosure

BioHarvest Sciences Inc. (NASDAQ: BHST) is a paid participant at our conference. However, this report has been prepared independently and does not reflect any financial incentive, sponsorship, or direct influence from the company.

Ownership Disclosure

The authors of this report do not hold, directly or indirectly, any stock, options, or financial interests in BioHarvest Sciences Inc. (NASDAQ: BHST) at the time of publication.

Forward-Looking Statements Disclaimer

This report contains forward-looking statements that involve known and unknown risks, uncertainties, and assumptions. These statements are based on available data and projections but are subject to change due to regulatory developments, financial performance, competitive pressures, and macroeconomic conditions. Investors should carefully review BioHarvest Sciences Inc.'s latest SEC filings, including its 10-K and 10-Q reports, for updated risk factors and financial disclosures. We assume no obligation to update or revise forward-looking statements as new information becomes available.

Legal Safeguards

This report is not a solicitation to buy or sell securities and should not be interpreted as financial advice. Neither the authors nor the publishing entity shall be held liable for any investment decisions made based on this report. Always conduct thorough due diligence before investing.